Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8927692
SERIAL NO

13883978

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • INOVIO PHARMACEUTICALS, INC.;THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ferraro, Bernadette Philadelphia, US 25 26
Ramanathan, Mathura P Ardmore, US 16 40
Sardesai, Niranjan Y Blue Bell, US 30 172
Weiner, David B Merion, US 186 1843
Yan, Jian Havertown, US 159 443

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 6, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00